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Abstract 
Complex I (NADH dehydrogenase, NDU) and complex IV (cytochrome-c-oxidase, COX) of 
the mitochondrial electron transport chain have been implicated in the pathophysiology of 
major psychiatric disorders such as major depressive disorder (MDD), bipolar disorder (BD) 
and schizophrenia (SZ), as well as in neurodegenerative disorders, such as Alzheimer disease 
(AD) and Parkinson disease (PD). 
We conducted meta-analyses comparing complex I and IV in each disorder MDD, BD, SZ, 
AD PD, as well as in normal aging. The electronic databases Pubmed, EMBASE, CENTRAL 
and Google Scholar, were searched for studies published between 1980 and 2018. Of 2049 
screened studies, 125 articles were eligible for the meta-analyses. Complex I and IV were 
assessed in peripheral blood, muscle biopsy, or postmortem brain at the level of enzyme 
activity or subunits.  
Separate meta-analyses of mood disorder studies, MDD and BD, revealed moderate effect 
sizes for similar abnormality patterns in the expression of complex I with SZ in frontal cortex, 
cerebellum and striatum, whereas evidence for complex IV alterations was low. By contrast, 
the neurodegenerative disorders, AD and PD, showed strong effect sizes for shared deficits in 
complex I and IV such as in peripheral blood, frontal cortex, cerebellum and substantia nigra. 
Beyond the diseased state, there was an age-related robust decline in both complexes I and 
IV. In summary, the strongest support for a role for complex I and/or IV deficits, is in the 
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Introduction 
Mitochondrial dysfunction is implicated in the pathophysiology of major psychiatric 
disorders, such as major depressive disorder (MDD) (Bansal and Kuhad, 2016), bipolar 
disorder (BD) (Kato, 2017) and schizophrenia (SZ) (Bergman and Ben-Shachar, 2016), as 
well as neurodegenerative disorders, such as Alzheimer disease (AD) (Onyango et al, 2017) 
and Parkinson disease (PD) (Onyango et al, 2017). Mitochondria are intracellular organelles 
that produce adenosine triphosphate (ATP), the main source of cellular energy. Impaired 
mitochondrial function results in decreased ATP production, impaired bioenergetics, 
apoptosis and oxidative stress (Hroudová and Fišar, 2011). Prior to the generation of ATP, 
mitochondria direct electrons extracted from nutrients into a transmembrane proton gradient 
and this process is mediated by the electron transport chain (ETC).  
Research has identified two enzymes of the ETC located at the inner mitochondrial membrane 
as being particular impaired in these five disorders MDD, BD, SZ, AD and PD. The first 
enzyme, complex I (NADH dehydrogenase, NDU) consists of 45 subunits, seven of which are 
encoded by mitochondrial DNA (mtDNA) and the remaining subunits by nuclear DNA 
(nDNA). Complex I is one of the entry enzymes of cellular respiration or oxidative 
phosphorylation in the mitochondrion. It is also the largest multimeric enzyme complex of the 
ETC and is a major contributor to the generation of the proton gradient across the 
mitochondrial inner membrane, which drives ATP production. The second enzyme of interest, 
complex IV (cytochrome-c-oxidase, COX) consists of 13 subunits, three of which are 
encoded by mtDNA, the remainder by nDNA. Complex IV catalyzes the final step in the 
mitochondrial ETC and, due to its rate-limiting role in this oxidative process (Arnold, 2012), 
has been proposed as a key markers of mitochondrial function (Srinivasan and Avadhani, 
2012). Numerous excellent reviews (Bansal and Kuhad, 2016; Bergman and Ben-Shachar, 
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complex I and IV enzyme activities and subunit assembly within each of the above mentioned 
disorders. A meta-analysis summarizing the findings across these disorders could not be 
found in the literature. The remaining complexes II (succinate dehydrogenase ), III 
(cytochrome c reductase) and V (ATP synthase) either have not been studied, or they have 
been studied to a much smaller degree in these five disorders, compared with complex I and 
IV, and thus there are too few data for a meta-analysis.  
We chose these five disorders MDD, BD, SZ, AD and PD not only because of the potential 
common mitochondrial dysfunction, but also based on their clinical similarities. Though 
regarded as different disorders in major classification systems like DSM and ICD, there is 
also overlap in clinical symptoms. Depression is found in mood disorders, but is also frequent 
in schizophrenia and both AD and PD (Lanctôt et al, 2017; Zhuo et al, 2017). Psychotic 
symptoms are observed in MDD and BD as well as SZ ((DSM-IV-TR), 2000). Although 
Alzheimer’s and Parkinson’s diseases have distinct brain histopathology, both are age-related 
neurodegenerative conditions characterized by memory loss and depression and have some 
commonality in molecular pathogenesis, such as proteinopathy, neuroinflammation and 
oxidative stress (Aarsland et al, 2001). Cross-disorder commonalities are also found in 
schizophrenia sharing dopaminergic abnormalities with Parkinson’s (Brisch et al, 2014) and 
cognitive impairment (dementia praecox) with Alzheimer’s (Lyketsos CG and Peters ME, 
2015).  
Beyond disease states, normal aging plays an independent role in mitochondrial ETC function 
(Sun et al, 2016). To separate the influence of age from that of disease, we therefore 
additionally meta-analyzed complex I and IV functioning in healthy older versus younger 
individuals. The present meta-analyses aimed to provide a synthesis of the work done on 
complex I and IV that can guide future research and stimulate development of novel in-vivo 
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NAD+/NADH ratio (Blacker and Duchen, 2016; Zhu et al, 2015) or oxidized complex IV 
(Bale et al, 2016). 
 
 
Materials and methods  
Literature search and study identification 
We conducted a structured literature search in PubMed, EMBASE, CENTRAL and Google 
Scholar, to identify studies published between January 1980 and January 2018 using the 
search strings ‘NADH dehydrogenase’ OR ‘cytochrome-c-oxidase’ OR ‘complex I’ OR 
‘complex IV’ AND ‘major depressive disorder’ OR ‘bipolar disorder’ OR ‘schizophrenia’ OR 
‘Alzheimer’ OR ‘Parkinson’ OR ‘age/aging’. We manually reviewed reference lists in all 
retrieved articles for related publications. 
Inclusion criteria were: studies investigated either complex I and/or complex IV, studies 
published in the English language, studies reporting original human data and studies that 
investigated patients in comparison with a control group. Exclusion criteria were: animal 
studies, cellular studies, genetic studies, studies with less than three subjects per group, case 
reports, letters to the editor and editorials and publications not reporting original data. 
Data extraction  
Aggregated data were extracted for each of the disorders MDD, BD, SZ, AD, PD and normal 
aging (AGING). Aggregated data contained quantitative data (i.e., number of patients and 
controls, mean age of patients and controls), qualitative information (i.e., methods such as 
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such as peripheral blood, muscle or brain regions of interest, ROIs) and outcomes (effect sizes 
in terms of the standardized mean difference, SMD, and p-values). Enzyme activity was 
extracted as a corrected ratio to citrate synthase to normalize for mitochondrial content, if 
available. For studies on AGING, we chose a breakpoint of mean 60 years (Cabré et al, 2017) 
to derive group differences between older (> 60) and younger (< 60) individuals using t-test. 
In case of medication reported in the studies, both un-medicated and medicated cohorts were 
included. In case of BD, data were included from both BD I and BD II during depressive 
episodes, but not manic episodes. 
The authors of some studies were contacted for permission to reuse original data (Altar et al, 
2005; Karry et al, 2004; Konradi C et al, 2004; Manczak et al, 2004; Thomas et al, 2012; 
Washizuka et al, 2005, 2009); no answer was received in some cases and the data could 
therefore not or only partially included (Altar et al, 2005; Konradi C et al, 2004; Manczak et 
al, 2004; Thomas et al, 2012). Some data were read from figures (Andreazza et al, 2013; 
Andreazza AC et al, 2010; Cabré et al, 2017; Chagnon et al, 1995; Chandrasekaran et al, 
1998; Devi et al, 2006; Distefano et al, 2017; Gatt et al, 2016; Gueugneau et al, 2015; Hsieh 
et al, 1994; Kim et al, 2016; Kish et al, 1992; Mehler-Wex et al, 2006; Munkholm et al, 
2015; Mythri et al, 2011; Ojaimi et al, 1999; Parker et al, 2008; Safdar et al, 2010; Simonian 
and Hyman, 1993, 1995; Trounce et al, 1989).  
Multivariate random-effect meta-analyses  
Separate meta-analyses were first computed for each disorder. Moderator variables were 
generated representing the combination of two aspects: 1) method (enzyme activity or 
subunit); and 2) tissue (blood, muscle or ROI). A moderator was included in the meta-analysis 
only if it was reported by at least three studies. This threshold was chosen after extensive 
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A summary meta-analysis was computed across all disorders. Here, the moderator variable 
consisted of the five disorders MDD, BD, SZ, AD, PD and AGING. This analysis included all 
data found to be eligible in the present work and thus also included rare outcomes that could 
not be included in the separate disease/aging meta-analyses.  
For all meta-analyses, a multivariate random-effect model was applied based on the Metafor 
package (Viechtbauer, 2010) as implemented in R (R Development Core Team, 2008). The 
multivariate model accounts for heterogeneity and dependency in the underlying true effects 
of multiple moderators that can overlap within subjects and studies (random factors). To 
adjust for age effects, the age-difference between patients and controls was added as a 
continuous covariate. To adjust for sample size, the effects were weighted based on study 
size. To allow for heterogeneity differences between moderators, an unstructured variance-
covariance matrix was applied (rma.mv function; observed effects = SMD + age-difference; 
variance-covariance matrix = COV; weight = study size; variance structure = UN; mods = 
moderators/disorder; random factors = subject/study; method = REML). 
Forest plots were generated to illustrate the results of the multivariate models in terms of the 
weighted beta coefficients with 95% confidence intervals (CIs) and p-values. Heterogeneity 
was assessed using Cochran's Q-test and the inconsistency I2 statistic that directly indicates to 
what extent each outcome contributes to the total variance. Publication bias was assessed 









Of 2049 screened studies, 125 studies were eligible for the meta-analyses, some of them for 
more than one disorder (MDD N = 7, BD N = 19, SZ N = 21, AD N = 43, PD N = 35, 
AGING N = 18) (Table 1). The overall number of studies reporting on complex I (total N = 
101, MDD N = 6, BD N = 19, SZ N = 15, AD N = 19, PD N = 32, AGING N = 11) and 
complex IV (total N = 104, MDD N = 4, BD N = 10, SZ N = 10, AD N = 39, PD N = 28, 
AGING N = 15) were similar but varied between disorders. Both complex I and IV were 
analysed in either peripheral blood elements, such as platelets, lymphocytes or other blood 
cells  (MDD N = 1, BD N = 10, SZ N = 8, AD N = 9, PD N = 14, AGING N = 2), in muscle 
biopsies (MDD N = 2, BD N = 0, SZ N = 0, AD N = 0, PD N = 9, AGING N = 14), or in 
postmortem brain samples (MDD N = 4, BD N = 8, SZ N = 13, AD N = 34, PD N = 14, 
AGING N = 2). Both complex I and IV were analysed at the level of enzymatic activity 
(either in blood, muscle, or brain, MDD N = 4, BD N = 5, SZ N = 11, AD N = 32, PD N = 32, 
AGING N = 14), or of their subunits by mRNA level (only brain, MDD N = 3, BD N = 7, SZ 
N = 7, AD N = 7, PD N = 1, AGING N = 2) or protein level (only brain, MDD N = 3, BD N = 
12, SZ N = 7, AD N = 6, PD N = 3, AGING N = 5). In the following, enzyme activity is 
denoted with NDU/COX respectively, whereas subunits as assessed by either mRNA or 
protein expression are referred to with their full names.  
Note that we combined data from levels of mRNA/protein expression for all subunits. The 
correlation between mRNA and protein expression is generally thought to be around 40% 
(Abreu et al, 2009; Vogel and Marcotte, 2012), which is typically attributed to other levels of 
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findings in a pre-analysis but found no significant differences between mRNA and protein 
expression and therefore presented the results together.   
Assay of enzyme activity was more common in studies of neurodegenerative disorders, AD 
(88%) and PD (66%), whereas the assessment of mRNA/protein expression was more 
common in studies of mood disorders, MDD (60%), BD (79%) and SZ (56%). None of the 
five disorders, however, showed differences in enzyme activity or mRNA/protein expression 
for complex I or IV (p > 0.05). Moreover, there were no differences between peripheral blood 
and brain in the enzyme activity/mRNA/protein levels of complex I and IV (p > 0.05).  
All studies involved subjects over 18 years old, except two studies examined early-onset SZ 
patients below age 18 years (Mehler-Wex et al, 2006; Taurines et al, 2010). The mean age-
difference between cases and controls differed between disorders (main effect F = 35.21, p < 
0.0001). Psychiatric studies, MDD (mean age-difference ± STD = -0.7 ± 3.9), BD (mean age-
difference ± STD = 0.8 ± 4.9) and SZ (mean age-difference ± STD = -1.0 ± 3.7) included 
closer age-matched cases and controls compared with AD (mean age-difference ± STD = 5.0 
± 7.5) or PD (mean age-difference ± STD = 5.3 ± 5.9) as indicated by significant post-hoc 
comparisons (p < 0.0001). Some studies did not provide mean ages for cases and/or controls 
(Cooper et al, 1993; DiDonato et al, 1993; Hirai et al, 2001; Reichmann et al, 1993; 
Wiedemann et al, 1999), for which we therefore assumed zero age-difference.  
Multivariate random-effect meta-analyses  
Meta-analyses were performed for each of the disorders MDD, BD, SZ, AD, PD and AGING. 
Based on the precondition that a moderator was reported at least three times across studies, 
the number of studies finally included in the meta-analyses (and the percentage of the eligible 




 10 of 37 
 
BD (complex I N = 16 (84%), complex IV N = 3 (30%)), SZ (complex I N = 14 (93%), 
complex IV N = 6 (60%)), AD (complex I N = 12 (63%), complex IV N = 33 (85%)), PD 
(complex I N = 29 (91%), complex IV N = 24 (86%) and AGING (complex I N = 7 (64%), 
complex IV N = 14 (93%)).  
Mood disorders 
In MDD (Figure 1a), complex I subunits NDUFS1cerebellum (p = 0.0075), NDUFV1cerebellum (p 
= 0.00014) and NDUFV2cerebellum (p = 0.00051) were lower in cerebellum and subunit 
NDUFV1frontal (p = 0.0047) was lower in frontal cortex compared with controls. No 
differences were found for complex IV (note that only in this case, we set the moderator 
threshold to at least two).  
In BD (Figure 1b), complex I subunit NDUFS1cerebellum (p < 0.0001) was lower in cerebellum, 
subunits NDUFS1frontal (p = 0.033) and NDUFS7frontal (p < 0.0001) were lower in frontal 
cortex and subunit NDUFS1striatum (p = 0.0023) was lower in striatum compared with controls. 
No differences were found for complex IV.  
In SZ (Figure 1c), complex I subunit NDUFV2blood (p = 0.019) was lower in blood, whereas 
subunit NDUFS1blood (p = 0.00086) was higher in blood compared with controls. Further, 
subunits NDUFS1striatum (p = 0.00072), NDUFV1striatum (p < 0.0001) and NDUFV2striatum (p < 
0.0001) were lower in striatum, subunit NDUFV1frontal (p = 0.011) was lower in frontal cortex, 
whereas subunit NDUFV2parietal (p = 0.019) was higher in parietal cortex compared with 
controls. Complex IV enzyme activity was lower in frontal cortex (COXfrontal p = 0.016), but 
higher in basal ganglia (COXNA/GP/P p< 0.0001, nucleus accumbens, globus pallidus and 
putamen) compared with controls. 
We also assessed the overlap in findings between MDD, BD and SZ using meta-regressions. 
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0.005/p = 0.001/p = 0.006) and in some subunits also BD (p = 0.088/p = 0.001/p = 0.258) 
compared to SZ, respectively. By contrast, lower NDUFS1/NDUFV1/NDUFV2 levels in 
striatum were observed in SZ compared to MDD (p = 0.001/p < 0.0001/p < 0.0001) and in 
some subunits also BD (p = 0.250/p < 0.0001/p < 0.0001), respectively. Further, both BD (p = 
0.024) and SZ (p = 0.008) revealed higher levels of NDUFV2 in the parietal cortex compared 
to MDD. Last, in BD, subunit NDUFS1blood levels (p = 0.002) in blood and subunit 
NDUFS7frontal (p = 0.009) in frontal cortex were lower compared to SZ.  
Neurodegenerative disorders 
In AD (Figure 2a), complex I enzyme activity in the temporal cortex (NDUtemporal/entorhinal p = 
0.0023) and subunits NDUFA1/4/7-9blood (p < 0.0001), NDUFB2/3/6blood (p < 0.0001) and  
NDUFS3/4/5blood (p < 0.0001) were lower in blood compared with controls. It should be noted 
that these subunits were reported by Lunnon et al. (Lunnon et al, 2012), which was the largest 
study eligible for the present work with a total of 209 subjects (patients N = 104, controls N = 
105). Initially only a small subset of that study could be included in the meta-analysis because 
of the high moderator threshold; in order to include more of the results from that study, we 
summarized results across subunits to build sufficient moderators. 
Complex IV enzyme activity was lower in frontal cortex (COXfrontal p = 0.044), motor cortex 
(COXmotor p = 0.0003), occipital cortex (COXocciptal p = 0.032), parietal cortex (COXparietal p = 
0.00069), temporal/entorhinal cortex (COXtemporal/entorhinal p = 0.00012) and hippocampus 
(COXhippocampus p < 0.0001) compared to controls. Subunit COX2hippocampus in hippocampus (p 
< 0.0001) and subunit COX7blood in peripheral blood (p = 0.011) were lower.  
In PD (Figure 2b), complex I enzyme activity in peripheral muscle (NDUmuscle p = 0.000084) 
as well as in substantia nigra (NDUsubstantia nigra p = 0.006) was lower compared to controls. 
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The overlap between AD and PD was assessed using meta-regressions. Results showed 
comparable patterns of enzyme activity in blood (COXblood p = 0.981) and brain such as in 
frontal cortex (NDUfrontal p = 0.171, COXfrontal p = 0.711), cerebellum (COXcerebellum p = 0.582) 
and substantia nigra (COXsubstantia nigra p = 0.671), indicating no significant differences between 
AD and PD. 
Aging 
To assess complex I and IV functioning in normal aging, we performed a separate meta-
analysis in healthy subjects using a breakpoint of 60 years (Cabré et al, 2017) (Figure 2c). 
Older (≥ 60 years) subjects in comparison with younger (< 60 years) subjects had lower 
complex I enzyme activity in frontal cortex (NDUfrontal p < 0.0001) and muscle (NDUmuscle p < 
0.0001, NDUFB8muscle p = 0.00015). Similarly, complex IV enzyme activity was lower in 
frontal cortex (COXfrontal p = 0.00072) and muscle (COXmuscle p = 0.00027, COX2muscle p < 
0.0001) in older compared to younger subjects.  
Summary comparison of all cases and controls  
A summary meta-analysis was performed to categorize the disorders according to the severity 
of overall mitochondrial impairments (Figure 3). Robust deficits were observed for complex I 
in PD (p = 0.0016) and AGING (p = 0.009) and for complex IV in AD (p = 0.004) and 
AGING (p < 0.0001). MDD (p < 0.0001) also showed an effect on complex I; however, it was 
based on small samples sizes from few studies and can therefore not be considered a robust 
result. The main effect across both complex I and IV was significant in PD (p = 0.00058), AD 
(p = 0.049) and AGING (p < 0.0001) indicating that these three conditions were also affected 
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Heterogeneity and publication bias 
Overall, there was a high degree of heterogeneity (Table 2). The I2 for the five disorders 
MDD, BD, SZ, AD and PD ranged between 80-100%. Noticeable, there was low 
heterogeneity in AGING in both complex I (Q = 27.934, p = 0.218, I2 = 18%) and IV (Q = 
11.684, p = 1, I2 = 0%). Putative low heterogeneity was observed in MDD for complex IV (Q 
= 0.030, p = 1, I2 = 0%), most likely explained by the fact that the data came from few studies 
(N = 4). 
Publication bias as assessed using Egger’s regression test (Table 2) provided non-significant 
results for most of the data indicating no publication bias. Considerable publication bias was 
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Discussion  
Our findings provide a picture of the current findings on complex I and IV in mood and 
neurodegenerative disorders (Figure 4).	We found that mood disorders, MDD and BD, share 
commonalities with SZ in having low expression of complex I subunits. Neurodegenerative 
disorders, AD and PD, share similarities in complex I and IV enzyme activity abnormalities. 
Due to heterogeneity in study findings, strong evidence for complex I and/or IV deficits is 
present for AD and PD, whereas the overall proof for the involvement of these complexes in 
MDD, BD and SZ is less robust and requires further research. Normal aging is a substantial 
independent factor contributing to both complex I and IV decline and should be considered 
when interpreting study heterogeneity.  
Mood disorders 
Mood disorders show shared patterns of complex I subunits NDUFS1, NDUFV1 and 
NDUFV2 between MDD and BD on the one hand, and between BD and SZ on the other hand 
(Figure 1) (Andreazza et al, 2013; Andreazza AC et al, 2010; Ben-Shachar and Karry, 2008; 
Iwamoto et al, 2005; Karry et al, 2004; Kim et al, 2016; Sun et al, 2006). While, MDD and to 
some degree BD, have lower levels of NDUFS1, NDUFV1, NDUFV2 in cerebellum 
compared with SZ, the latter had lower NDUFS1, NDUFV1, NDUFV2 levels in striatum 
compared with MDD and to some degree BD; this indicates a shared mechanism between 
MDD and BD that is distinct from SZ. By contrast, BD and SZ had elevated levels of 
NDUFV2 in parietal cortex compared with MDD, which may indicate a shared mechanism 
between BD and SZ. These brain regions, i.e., the frontal cortex (Brakowski et al, 2017; 
Hibar et al, 2017), cerebellum (Jiang et al, 2017; Shinn et al, 2017) and striatum (Pacifico and 
Davis, 2016), have been previously suggested to contribute to the pathophysiology of mood 
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disorders, SZ has higher complex IV levels in basal ganglia (Prince et al, 1999, 2000) perhaps 
related to previous neuropathological findings in putamen, nucleus accumbens and globus 
pallidus (Mamah et al, 2007; Womer et al, 2014).  
Notably, while most of the eligible studies pointed to dysregulation of complex I and/or IV, 
the reported direction of change has not always been consistent. While some of the 
heterogeneity may be due to potential differences in the clinical picture like presence of 
psychosis in MDD or BD and presence of depression in SZ, several other explanations may 
underlie these discrepancies. First, there may be state-related differences in the expression of 
complex I and IV. For example BD patients showed up-regulation of complex I subunits 
during manic compared to depressive episodes (Akarsu et al, 2015) maybe related to elevated 
brain metabolism in frontal and temporal cortex (Shao et al, 2008). Similarly in SZ, state-
dependence has been suggested with increased complex I activity in active psychotic patients 
but decreased activity in patients with residual schizophrenia (Ben-Shachar et al, 2007; Dror 
et al, 2002; Rosenfeld et al, 2011). Unfortunately, postmortem studies were unable to provide 
information on whether patients were depressed, manic or euthymic at time of death. Second, 
there may be brain region-specific heterogeneity, possibly indicating that ETC energy 
production varies from region to region, as previously exemplarily shown (Ben-Shachar and 
Karry, 2008). Third, there may be tissue-specific differences between blood samples from 
living patients and brain samples obtained postmortem. For example, it has been hypothesized 
that ETC genes are up-regulated in blood, but down-regulated in some or all brain regions in 
BD (Beech et al, 2010) and SZ (Ben-Shachar and Karry, 2007), although this was not 
confirmed statistically by the present meta-analysis. Fourth, the majority of patients were 
receiving psychotropic medication, such as antidepressants, mood stabilizers and 
antipsychotics. All of these pharmacological agents have been reported to potentially interfere 
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the time of death may explain difference in gene expression (Vawter et al, 2006). Larger 
sample studies of medication-free patients are needed to clarify more precisely the 
relationships between diagnosis, mood state, treatment status and brain pH in mood disorders 
and schizophrenia pathophysiology. There is also evidence of shared global gene expression 
patterns between mood disorders and schizophrenia that go beyond purely mitochondrial 
function that could be investigated in relation (Gandal et al, 2018).  
Neurodegenerative disorders 
Neurodegenerative disorders AD and PD show similarities in the impairment of complex I 
and IV enzyme activities in the blood, frontal cortex, cerebellum and substantia nigra (Figure 
2). These brain regions are potentially involved in the cognitive decline and neuronal loss in 
AD (Boublay et al, 2016; Perluigi et al, 2016) as well as in the motor and non-motor related 
degeneration of neurotransmitter systems in PD (Atkinson-Clement et al, 2017; Gao and Wu, 
2016).  
In AD, there are a well-documented deficit in both complex I and IV (Coskun et al, 2012; 
Giachin et al, 2016; Onyango et al, 2017). These deficits are thought to be due to the neuronal 
toxicity induced by amyloid β peptide (Aβ), an important component of AD pathogenesis, in 
that Aβ accumulates in mitochondria, directly inhibits mitochondrial enzymes, perpetuates 
oxidative stress, and leads to a hypometabolic state, which causes mitochondrial dysfunction 
(Cenini et al, 2016; Picone et al, 2014; Pinho et al, 2014; Readnower et al, 2011). The meta-
analysis supported these findings in terms of down-regulated complex I and IV in the blood 
(Cardoso et al, 2004; Feldhaus et al, 2011; Fišar et al, 2016; Lunnon et al, 2012; Mancuso et 
al, 2003; Parker et al, 1990, 1994a; Sheehan et al, 1997; Valla et al, 2006), frontal cortex 
(Cavelier et al, 1995; Devi et al, 2006; Hirai et al, 2001; Kish et al, 1992; Long et al, 2012; 
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motor cortex (Bosetti et al, 2002; Valla et al, 2001; Wong-Riley et al, 1997), occipital cortex 
(Kish et al, 1992, 1999; Mutisya et al, 1994), parietal cortex (Chagnon et al, 1995; Kish et al, 
1992, 1999; Mutisya et al, 1994; Reichmann et al, 1993; Wong-Riley et al, 1997), 
temporal/entorhinal cortex (Alikhani et al, 2011; Chandrasekaran et al, 1998; Cooper et al, 
1993; Gu et al, 1998; Kish et al, 1992, 1999; Maurer et al, 2000; Mutisya et al, 1994; 
Reichmann et al, 1993; Wong-Riley et al, 1997) and hippocampus (Aksenov et al, 1999; 
Bosetti et al, 2002; Chagnon et al, 1995; Chandrasekaran et al, 1994; Cottrell et al, 2001; 
Kish et al, 1992; Maurer et al, 2000; Reichmann et al, 1993; Simonian and Hyman, 1993, 
1995; Verwer et al, 2000; Wong-Riley et al, 1997). The strength of the effect sizes are in line 
with findings of neuronal loss in entorhinal cortex, hippocampus and association neocortex 
(Perluigi et al, 2016). Due to limited data, the meta-analysis was not able to distinguish 
between Brack stages in AD. A large study in AD (N = 148) reported less expression of 
complex I and IV subunits in entorhinal and frontal cortex in disease stages V-VI but not in 
stages I -II (Armand-Ugon et al, 2017). A smaller study (N = 18) compared complex I and IV 
enzyme activity in frontal cortex in stages III-VI to stages I-II but found no stage-dependence 
(Manczak et al, 2004). There were also no differences between early- versus late-onset AD 
(age < 60 versus age > 60) (Cardoso et al, 2004).  
In PD, the meta-analysis points to down-regulation of both complex I and IV enzyme activity 
in the blood, muscle and brain. For example, inhibition of complex I has been reported in 
platelets (Benecke et al, 1993; Blake et al, 1997; Bravi et al, 1992; Gu et al, 1998; Krige et al, 
1992; Parker et al, 1989; Varghese et al, 2009; Yoshino et al, 1992) and skeletal muscles 
(Bindoff et al, 1991; Blin et al, 1994; Cardellach et al, 1993; Nakagawa-Hattori et al, 1992; 
Shoffner et al, 1991), although there was dissenting studies in platelets (Bronstein et al, 2015; 
Martín et al, 1996) or muscle (Anderson et al, 1993; DiDonato et al, 1993; Mann et al, 1992). 
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al, 1992; Haas et al, 1995; Krige et al, 1992; Parker et al, 1989; Shinde and Pasupathy, 2006) 
and muscle (Anderson et al, 1993; Bindoff et al, 1991; Cardellach et al, 1993; Shoffner et al, 
1991), while others could not confirm this for either platelets (Blake et al, 1997; Hanagasi et 
al, 2005) or muscle (Blin et al, 1994; DiDonato et al, 1993; Mann et al, 1992; Nakagawa-
Hattori et al, 1992; Wiedemann et al, 1999). Within the brain, some studies reported lower 
complex I enzyme activity in substantia nigra (Gu et al, 1998; Mann et al, 1992; Mizuno et al, 
1990; Schägger, 1995; Schapira et al, 1990b) as well as low activity and impaired assembly 
of complex I in frontal cortex (Barroso et al, 1993; Gatt et al, 2016; Keeney et al, 2006; 
Mizuno et al, 1990; Mythri et al, 2011; Parker et al, 2008), the latter not being confirmed in 
the meta-analysis. Similarly, complex IV in the brain is reported to be low in frontal cortex 
(Barroso et al, 1993; Chagnon et al, 1995; Keeney et al, 2006; Mizuno et al, 1990; Parker et 
al, 2008) and substantia nigra (Chagnon et al, 1995; Gu et al, 1998; Mann et al, 1992; 
Schägger, 1995; Schapira et al, 1990a), the latter finding not confirmed here. Note that 
although all data eligible for the meta-analysis were obtained from patients suffering from the 
more common sporadic form of PD, derangements in mitochondrial metabolism and oxidative 
stress have also been strongly linked to the less common familial form of PD (Ryan et al, 
2015).  
Likewise for mood disorders, medication may affect mitochondrial functioning in 
neurodegeneration. Cholinesterase (ChE) inhibitors and amyloid-beta binding alcohol 
dehydrogenase (ABAD) modulators are used to treat the key symptoms in AD in order to 
improve activities of daily living, behavior and cognition (Grossberg, 2003). Most of these 
drugs can negatively affect both complex I and IV (Hroudová et al, 2017). There are however 
newly developed ChEs and ABADs as well as other more recent drug developments that 
target multiple AD pathophysiological pathways that are thought to have a better outcome on 
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selegiline, which are used to treat PD motor symptoms, have not been shown not affect 
complex I and IV in PD (Dixit et al, 2013; Shults et al, 1995). Similarly, melatonin that is 
used as sleep/wake regulator in PD, acts as an effective antioxidant and mitochondrial 
function protector (Srinivasan et al, 2011). These observations support the hypothesis that 
impaired complex I and IV activity in PD patients is a characteristic of the disease and not 
due to medications. 
Aging 
Normal aging has been associated with a decline in mitochondrial quality (Sun et al, 2016) 
and activity of both complex I and IV (Arnold, 2012; Navarro and Boveris, 2007). The meta-
analysis supported these findings in terms of  decreased levels of enzyme activity in the 
muscle (Boffoli et al, 1996; Distefano et al, 2017; Emelyanova et al, 2017; Gueugneau et al, 
2015; Hsieh et al, 1994; Lanza et al, 2008; Ogborn et al, 2015; Pestronk et al, 2017; 
Rooyackers et al, 1996; Safdar et al, 2010; Zucchini et al, 1995) and frontal cortex (Boffoli et 
al, 1994, 1996; Cabré et al, 2017; Ojaimi et al, 1999) (Figure 2c). Across all meta-analyses, 
the effect of aging was the most robust both in terms of the strength of the summary effect 
sizes (Figure 3) as well as the low degree of heterogeneity (Table 2).  
The decline in both complex I and IV in normal aging (Arnold, 2012; Navarro and Boveris, 
2007) as indicated by this meta-analysis can represent a functionally serious impairment of 
mitochondrial function with respect to basal ATP production (Boveris et al, 1999). Therefore, 
aged neurons with lower mitochondrial mass and enzyme activities as well as more 
dysfunctional mitochondria may be unable to respond adequately to any increased ATP 
demand (Navarro and Boveris, 2004).  
The term normal aging should be considered carefully. Normal aging is thought to be a 
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underlying mechanism is still controversial, age-dependent mitochondrial decline may 
contribute to loss of physical capacity and mental exertion (Christian and Shadel, 2014; Payne 
and Chinnery, 2015). The ‘free radical’ theories of aging (Harman, 1992; Miquel et al, 1980) 
state that reactive oxygen species (ROS) produced aberrantly during mitochondrial electron 
transport damage mitochondrial components, including mtDNA. Since, mtDNA encodes 
essential complex I and IV proteins (Bonawitz et al, 2006), its damage and mutagenesis 
would disrupt ETC complex assembly and, in turn, lead to more ROS production, cellular 
oxidative stress and tissue dysfunction that promote aging (Mandavilli et al, 2002). This 
theory, however, has been thought to be too simplistic and there is debate about other age-
dependent cellular changes that may be as important in precipitating the decline in 
mitochondrial ETC (Christian and Shadel, 2014). 
Summary comparison of all cases and controls  
Summarizing the overall severity of mitochondrial impairment in the five disorders (Figure 
3) indicates that major psychiatric disorders MDD, BD and SZ show less robust effects. The 
small effect sizes in those pathologies were most likely due to the small number of studies 
with small sample sizes, large region-specific heterogeneity and variation in medication and 
treatment, which made in harder to detect underlying mitochondrial disease. By contrast, 
strong evidence for a complex I deficit is found in PD, whereas a complex IV deficit is 
present in AD; with the simultaneous decline in complex I and IV being significant in both 
AD and PD. These results indicate an interaction of complex I with IV involved in the 
assembly and stability of complex I (Diaz et al, 2006; Li et al, 2007; Schäfer et al, 2007).   
The interpretation of the strengths of the effect sizes between the five disorder compared with 
normal aging, as shown in Figure 3, should however be cautious. Aging is a major risk factor 
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Consequently, the effects of normal aging and that of the diseases cannot be clearly separated 
because of their inter-dependence. Of note, patients in all studies included were age-matched, 
thus in principle presenting age-adjusted effects. We therefore argue that the lesser effects in 
mood disorders is not related to the younger age of these patients, and the larger effects in AD 
is also not related to older age.  
Further research is required to enlarge sample sizes and strengthen the evidence base. Our 
results may stimulate the application of novel in-vivo technologies such as assessing complex 
I NAD+/NADH redox state via auto-fluorescence (Blacker and Duchen, 2016) or magnetic 
resonance spectroscopy (Zhu et al, 2015) and complex IV redox states via functional near-
infrared spectroscopy (Bale et al, 2016). 
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Figure legends 
Figure 1. Forest plots MDD, BD and SZ. Multivariate random-effect estimates of the SMD 
(95% CI, p-values) of complex I (NDU) and IV (COX) enzyme activity and subunits are 
shown both in numerical and graphical form. Values lower than 0 indicate that patients had 
lower levels than controls (CO), and vice versa for values greater than 0; the dashed vertical 
line at SMD = 0 indicates no effect. The size of the filled circles for each estimated SMD is 
proportional to the weight of the studies. P = putamen, NA = nucleus accumbens, GP = 
globus pallidus.  
Figure 2. Forest plots AD, PD and AGING. Multivariate random-effect estimates of the 
SMD (95% CI, p-values) of complex I (NDU) and IV (COX) enzyme activity and subunits 
are shown both in numerical and graphical form. Values lower than 0 indicate that patients (or 
older (O) individuals) had lower levels than controls (CO) (or younger (Y) individuals), and 
vice versa for values greater than 0; the dashed vertical line at SMD = 0 indicates no effect. 
The size of the filled circles for each estimated SMD is proportional to the weight of the 
studies. 
Figure 3. Forest plot Summary. Multivariate random-effect estimates of the SMD (95% CI, 
p-values) of complex I and IV are shown both in numerical and graphical form. SMD are 
ordered according to their strengths. Values lower than 0 indicate that patients (P) had lower 
levels than controls (CO), and vice versa for values greater than 0; the dashed vertical line at 
SMD = 0 indicates no effect. The size of the filled circles for each estimated SMD is 
proportional to the weight of the studies.  
Figure 4. Schematic overview of our findings. Highlighted are the main findings of the 
meta-analyses for the five disorders MDD, BD, SZ, AD, PD and normal aging. Region-
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variation from ROI to ROI); tissue-specific heterogeneity indicates that complex levels vary 
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Tables 
Table 1. Eligible studies. 125 studies were eligible for the meta-analyses, part of which was 
included in the meta-analyses for complex I and IV (marked in gray). Some studies reported 
more than one disorder. The detailed data extracted from these studies are provided in the 
supplementary materials (Tables S1-6).  
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Table 2. (Top) Heterogeneity and Inconsistency. Significant Q statistics indicates the 
existence of heterogeneity. A I2 value of 0% indicates no observed inconsistency, whereas 
larger values shows increasing inconsistency. (Bottom) Egger's regression test for funnel 
plot asymmetry. The existence of funnel plot asymmetry and potential publication bias is 
indicated by p-values < 0.05. df = degrees of freedom.   
Heterogeneity and Inconsistency 




Complex I 549.160 0.000 91% 
Complex IV 0.030 1.000 0% 
BD 
Complex I 137410.000 0.000 100% 
Complex IV 873.150 0.000 95% 
SZ 
Complex I 2197.500 0.000 97% 
Complex IV 209.560 0.000 88% 
AD 
Complex I 64812.000 0.000 100% 
Complex IV 4490.300 0.000 97% 
PD 
Complex I 437.650 0.000 80% 
Complex IV 3083.300 0.000 99% 
AGING 
Complex I 27.934 0.218 18% 
Complex IV 11.684 1.000 0% 
Egger's regression  
    z-value df p-value 
MDD 
Complex I -1.969 4 0.120 
Complex IV 0.630 2 0.593 
BD 
Complex I -2.191 17 0.043 
Complex IV -0.042 8 0.968 
SZ 
Complex I 0.135 13 0.895 
Complex IV 1.035 8 0.331 
AD 
Complex I -0.109 17 0.915 
Complex IV -1.381 37 0.176 
PD 
Complex I -2.127 30 0.042 
Complex IV -0.176 26 0.862 
AGING 
Complex I -1.025 9 0.332 
Complex IV -2.820 13 0.014 
 




